Introduction and listing status of viloxazine hydrochloride

Viloxazine Hydrochloride is a new type of selective norepinephrine reuptake inhibitor (NRI) and serotonin reuptake inhibitor (SSRI). It is primarily used to treat attention deficit hyperactivity disorder (ADHD), especially in children and adolescents. Veloxazine helps improve patients' attention, impulse control and behavioral problems by regulating levels of norepinephrine and serotonin in the brain. The drug's unique mechanism of action gives it certain advantages over other medications used to treat ADHD.

Veloxazine was originally developed by German pharmaceutical company Hapilabs and received marketing approval for the European market. In 2021, veloxazine was approved by the FDA in the United States by Eisai, becoming the first NRI drug specifically used to treat ADHD. Its approval brings new options to the field of ADHD treatment, especially for patients who do not respond well to traditional treatment options, such as central nervous system stimulants.

In the United States, veloxazine is marketed under the trade name Qelbree and is primarily used to treat ADHD in children and adolescents aged 6 years and older. Its launch has received widespread attention because it provides a treatment modality that does not rely on central nervous system stimulants, and is especially suitable for patients who are not suitable to use stimulant drugs due to side effects or risk of abuse. In addition, veloxazine has also been approved in some other countries, especially in the European market, and is gradually being promoted as an ADHD treatment drug.
Although veloxazine is gradually gaining acceptance globally, it is still relatively new and expensive. In the European and American markets, veloxazine is relatively expensive, which makes some patients face a financial burden. As patents expire, it is expected that generic drugs may enter the market, thereby lowering the price of the drug and increasing its accessibility. However, veloxazine is still considered an important ADHD treatment option, especially for patients who require non-stimulant treatment options.
Reference: https://www.qelbree.com/